James C. Lo

James C. Lo

Auto-generated profile, based on publicly available information

James C. Lo

Division of Cardiology, Department of Medicine, Cardiovascular Research Institute, Weill Center for Metabolic Health, Weill Cornell Medicine

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Nature
Verified
Journal Article
Open access
PDF file
GWGang Wang
Gang Wang
JLJianlong Li
Jianlong Li
LBLinda Bojmar
Linda Bojmar
HCHaiyan Chen
Haiyan Chen
ZLZhong Li
Zhong Li
DLDavid Lyden
David Lyden
Cancer alters the function of multiple organs beyond those targeted by metastasis1,2. Here we show that inflammation, fatty liver and dysregulated metabolism are hallmarks of systemically affected livers in mouse models and in patients with extrahepatic metastasis. We identified tumour-derived extracellular vesicles and particles (EVPs) as crucial mediators of cancer-induced hepatic reprogramming, which could be reversed by reducing tumour EVP secretion via depletion of Rab27a. All EVP subpopulations, exosomes and principally exomeres, could dysregulate hepatic function. The fatty acid cargo of tumour EVPs—particularly palmitic acid—induced secretion of tumour necrosis factor (TNF) by Kupffer cells, generating a pro-inflammatory microenvironment, suppressing fatty acid metabolism and oxidative phosphorylation, and promoting fatty liver formation. Notably, Kupffer cell ablation or TNF blockade markedly decreased tumour-induced fatty liver generation. Tumour implantation or pre-treatment with tumour EVPs diminished cytochrome P450 gene expression and attenuated drug metabolism in a TNF-dependent manner. We also observed fatty liver and decreased cytochrome P450 expression at diagnosis in tumour-free livers of patients with pancreatic cancer who later developed extrahepatic metastasis, highlighting the clinical relevance of our findings. Notably, tumour EVP education enhanced side effects of chemotherapy, including bone marrow suppression and cardiotoxicity, suggesting that metabolic reprogramming of the liver by tumour-derived EVPs may limit chemotherapy tolerance in patients with cancer. Our results reveal how tumour-derived EVPs dysregulate hepatic function and their targetable potential, alongside TNF inhibition, for preventing fatty liver formation and enhancing the efficacy of chemotherapy.

16 September 2021 in Cell Metabolism
Verified
Journal Article
Closed access
MRMoritz Reiterer
Moritz Reiterer
MRMangala Rajan
Mangala Rajan
NGNicolás Gómez-Banoy
Nicolás Gómez-Banoy
JLJennifer D. Lau
Jennifer D. Lau
LGLuis G. Gomez-Escobar
Luis G. Gomez-Escobar
JLJames C. Lo
James C. Lo

7 November 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NGNicolás Gómez-Banoy
Nicolás Gómez-Banoy
JGJ. Sawalla Guseh
J. Sawalla Guseh
GLGe Li
Ge Li
ARAlfonso Rubio-Navarro
Alfonso Rubio-Navarro
TCTong Chen
Tong Chen
JLJames C. Lo
James C. Lo

19 January 2024 in Diabetes
Verified
Journal Article
Open access
PDF file
AGAnkit Gilani
Ankit Gilani
LSLisa Stoll
Lisa Stoll
EHEdwin A. Homan
Edwin A. Homan
JLJames C. Lo
James C. Lo
Excessive adiposity in obesity is a significant risk factor for development of type 2 diabetes (T2D), nonalcoholic fatty liver disease, and other cardiometabolic diseases. An unhealthy expansion of adipose tissue (AT) results in reduced adipogenesis, increased adipocyte hypertrophy, adipocyte hypoxia, chronic low-grade inflammation, increased macrophage infiltration, and insulin resistance. This ultimately culminates in AT dysfunction characterized by decreased secretion of antidiabetic adipokines such as adiponectin and adipsin and increased secretion of proinflammatory prodiabetic adipokines including RBP4 and resistin. This imbalance in adipokine secretion alters the physiological state of AT communication with target organs including pancreatic β-cells, heart, and liver. In the pancreatic β-cells, adipokines are known to have a direct effect on insulin secretion, gene expression, cell death, and/or dedifferentiation. For instance, impaired secretion of adipsin, which promotes insulin secretion and β-cell identity, results in β-cell failure and T2D, thus presenting a potential druggable target to improve and/or preserve β-cell function. The cardiac tissue is affected by both the classic white AT–secreted adipokines and the newly recognized brown AT (BAT)-secreted BATokines or lipokines that alter lipid deposition and ventricular function. In the liver, adipokines affect hepatic gluconeogenesis, lipid accumulation, and insulin sensitivity, underscoring the importance of adipose-liver communication in the pathogenesis of nonalcoholic fatty liver disease. In this perspective, we outline what is currently known about the effects of individual adipokines on pancreatic β-cells, liver, and the heart.

16 March 2023 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ARAlfonso Rubio-Navarro
Alfonso Rubio-Navarro
NGNicolás GómEz-Banoy
Nicolás GómEz-Banoy
LSLisa Stoll
Lisa Stoll
FDFriederike Dündar
Friederike Dündar
AMAlex M. Mawla
Alex M. Mawla
JLJames C. Lo
James C. Lo

5 December 2018 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
MPMaria A. Pabon
Maria A. Pabon
KMKevin Manocha
Kevin Manocha
JCJim W. Cheung
Jim W. Cheung
JLJames C. Lo
James C. Lo
Obesity and atrial fibrillation have risen to epidemic levels worldwide and may continue to grow over the next decades. Emerging evidence suggests that obesity promotes atrial and ventricular arrhythmias. This has led to trials employing various strategies with the ultimate goal of decreasing the atrial arrhythmic burden in obese patients. The effectiveness of these interventions remains to be determined. Obesity is defined by the expansion of adipose mass, making adipocytes a prime candidate to mediate the pro-arrhythmogenic effects of obesity. The molecular mechanisms linking obesity and adipocytes to increased arrhythmogenicity in both the atria and ventricles remain poorly understood. In this focused review, we highlight areas of potential molecular interplay between adipocytes and cardiomyocytes. The effects of adipocytes may be direct, local or remote. Direct effect refers to adipocyte or fatty infiltration of the atrial and ventricular myocardium itself, possibly causing increased dispersion of normal myocardial electrical signals and fibrotic substrate of adipocytes that promote reentry or adipocytes serving as a direct source of aberrant signals. Local effects may originate from nearby adipose depots, specifically epicardial adipose tissue (EAT) and pericardial adipose tissue, which may play a role in the secretion of adipokines and chemokines that can incite inflammation given the direct contact and disrupt the conduction system. Adipocytes can also have a remote effect on the myocardium arising from their systemic secretion of adipokines, cytokines and metabolites. These factors may lead to mitochondrial dysfunction, oxidative stress, autophagy, mitophagy, autonomic dysfunction, and cardiomyocyte death to ultimately produce a pro-arrhythmogenic state. By better understanding the molecular mechanisms connecting dysfunctional adipocytes and arrhythmias, novel therapies may be developed to sever the link between obesity and arrhythmias.